Cell line · CVCL_0080
Papers84
1 to 20 of 84
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Detection of Extracellular Vesicles with Colocalized Surface Markers via a Capture-Release-Capture Strategy for Treatment Monitoring in Ewing Sarcoma. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing Sarcoma. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. | J Hematol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape. | J Cell Commun Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| DiPRO1 distinctly reprograms muscle and mesenchymal cancer cells. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Temporal dynamics and stoichiometry in human Notch signaling from Notch synaptic complex formation to nuclear entry of the Notch intracellular domain. | Dev Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| USP1 Expression Driven by EWS::FLI1 Transcription Factor Stabilizes Survivin and Mitigates Replication Stress in Ewing Sarcoma. | Mol Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0080/papers